Disease
Non-Small Cell Lung Cancer
The most common form of lung cancer (~77% of cases), spanning adenocarcinoma, squamous cell carcinoma, and large cell carcinoma histologies. Treatment is heavily biomarker-driven -- EGFR, ALK, KRAS G12C, MET exon 14, ROS1, RET, HER2, and PD-L1 status each define a distinct targeted-therapy or immunotherapy pathway.
Coverage in progress. AssetMemo has not yet run its full census for Non-Small Cell Lung Cancer with MET Exon 14 Skipping, Non-Small Cell Lung Cancer with EGFR Mutations, Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer, ROS1-Positive Non-Small Cell Lung Cancer, ALK-Positive Non-Small Cell Lung Cancer, HER2-Mutant Non-Small Cell Lung Cancer, so the assets listed for them are not complete.
Combined attributable cost
$12.5B+
Drug spend
$4.8B+
38% of total cost is drugs
Sum of 7 indications below.